Kuck K H
Abt. Kardiologie, Universitätskrankenhaus Eppendorf.
Z Kardiol. 1992;81 Suppl 4:151-5.
The suppression by antiarrhythmic drugs of ventricular premature beats, pairs and salvos is frequently not associated with a suppression of ventricular tachycardia or fibrillation in the same patient. The evaluation of antiarrhythmic drugs must therefore distinguish between antiectopic, anti-reentry and anti-fibrillatory efficacy. Clinical methods such as Holter monitoring and programmed electrical stimulation which only allow the validation of anti-ectopic or anti-reentry efficacy present a major problem in the evaluation of antiarrhythmic drugs. Anti-fibrillatory drug efficacy cannot be evaluated by clinical methods.
抗心律失常药物对室性早搏、成对早搏及短阵室性心动过速的抑制作用，在同一患者中常常与对室性心动过速或心室颤动的抑制作用无关。因此，对抗心律失常药物的评估必须区分抗异位搏动、抗折返及抗颤动的疗效。诸如动态心电图监测和程控电刺激等临床方法，仅能验证抗异位搏动或抗折返的疗效，在抗心律失常药物评估中存在重大问题。抗颤动药物的疗效无法通过临床方法进行评估。
